Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MEETINGS - the International Symposium on Diabetic Retinopathy (India) September 2005:

This article was originally published in Clinica

Executive Summary

Aravind Eye Hospital and the Technology Information, Forecasting and Assessment Council - Centre of Relevance and Excellence (TIFAC-CORE) are hosting the International Symposium on Diabetic Retinopathy on September 3-4 2005, at the Aravind Eye Hospital, Madurai, India. Areas to be discussed between specialists from India and the Joslin Diabetes Centre, Boston, include: epidemiology and magnitude of diabetic retinopathy; recent trends in diabetes management; diagnosis; medical management of diabetic retinopathy; optical coherence tomography; service delivery model for diabetic retinopathy; telemedicine in diabetic retinopathy; and genetic research. For further information and to register, visit: http://www.aravind.org

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT055801

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel